On March 18, 2021 VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients’ cytotoxic T-cells targeting a wide range of cancer-related antigens, reported that the Company will participate in several scientific and industry events in the coming weeks (Press release, Vaximm, MAR 18, 2021, View Source [SID1234576853]). All conferences will be held virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

15th Annual International Partnering Conference BIO-Europe Spring
March 22-25, 2021
Dr. Heinz Lubenau, Chief Executive Officer and Co-Founder, will give a company presentation and participate in the online partnering system. To request a meeting, please sign up through the event’s partneringONE meeting system.

European Biotech Investor Days 2021
April 7-8, 2021
Dr. Lubenau will give a company presentation at 5pm CEST, 7 April, and be available for one-on-one meetings.

American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting
April 10-15 and May 17-21, 2021
Dr. Lubenau will attend the conference. To schedule a meeting with the Company, please contact [email protected].

Alliance for Cancer Gene Therapy Summit 2021
April 29, 2021
Dr. Lubenau will attend the conference. To schedule a meeting with the Company, please contact [email protected].

Upcoming events in which VAXIMM will participate are updated on a regular basis. See the Events section of the Company’s website for more information.